| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00003-2327-11 | 00003-2327 | Ipilimumab | Yervoy | 5.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Mar 25, 2011 | In Use | |
| 83257-0009-11 | 83257-0009 | Bevacizumab-nwgd | JOBEVNE | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 10, 2025 | In Use | |
| 50242-0088-01 | 50242-0088 | ADO-Trastuzumab Emtansine | Kadcyla | 20.0 mg/mL, 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | HER2 | Intravenous | Feb 22, 2013 | In Use | |
| 85006-1754-01 | 85006-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Mar 30, 2026 | In Use | |
| 83616-0107-11 | 83616-0107 | Vusolimogene oderparepvec-wtpg | Tudriqev | 10000000.0 [PFU]/mL | Immunotherapy | Oncolytic Viral Therapy | GALV-GP-R, GM-CSF | INTRATUMOR | Sep 4, 2026 | In Use | |
| 00006-5083-01 | 00006-5083 | Pembrolizumab and berahyaluronidase alfa-pmph | KEYTRUDA QLEX | 2000.0 U/mL, 165.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Sep 19, 2025 | In Use | |
| 70377-0054-11 | 70377-0054 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
| 83616-0106-11 | 83616-0106 | Vusolimogene oderparepvec-wtpg | Tudriqev | 1000000.0 [PFU]/mL | Immunotherapy | Oncolytic Viral Therapy | GALV-GP-R, GM-CSF | INTRATUMOR | Sep 4, 2026 | In Use | |
| 00004-0357-99 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Aug 22, 2011 | Sep 19, 2014 | No Longer Used |
| 00781-2358-27 | 00781-2358 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 1, 2026 | In Use | |
| 43598-0517-01 | 43598-0517 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 31, 2026 | In Use | |
| 16729-0692-09 | 16729-0692 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Apr 8, 2026 | In Use | |
| 61755-0056-01 | 61755-0056 | Linvoseltamab-gcpt | LYNOZYFIC | 200.0 mg/10mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Intravenous | Jul 2, 2025 | In Use | |
| 57894-0502-05 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Oct 31, 2024 | In Use |
| 57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2024 | In Use |
| 69097-0039-07 | 69097-0039 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 30, 2026 | In Use | |
| 51144-0030-01 | 51144-0030 | ENFORTUMAB VEDOTIN | PADCEV | 30.0 mg/3mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
| 70095-0058-01 | 70095-0058 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 31, 2026 | In Use | |
| 70095-0060-01 | 70095-0060 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 31, 2026 | In Use | |
| 72205-0178-91 | 72205-0178 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 72205-0179-21 | 72205-0179 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 69097-0038-07 | 69097-0038 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 30, 2026 | In Use | |
| 61755-0054-01 | 61755-0054 | Linvoseltamab-gcpt | LYNOZYFIC | 5.0 mg/2.5mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Intravenous | Jul 2, 2025 | In Use | |
| 87262-0160-02 | 87262-0160 | Afamitresgene autoleucel | TECELRA | 10000000000.0 1/1 | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | Intravenous | Jan 19, 2026 | In Use | |
| 00085-4347-01 | 00085-4347 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Aug 30, 2014 | Oct 18, 2020 | In Use |
Found 12611 results — Export these results
Home